Siyuan Cui

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Acute Myeloid Leukemia

Tyrosine Kinase

Replacement Therapy

Top Venues

Current medicinal chemistry

Journal of healthcare engineering

This page only lists publications with an associated author ORCID identifier.

Publications

Chenchen Ma, Siyuan Cui, Ruirong Xu
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment. Current medicinal chemistry 31 (29) (2024)
Chenchen Ma, Siyuan Cui, Ruirong Xu
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment. Current medicinal chemistry (2024)
Chenchen Ma, Siyuan Cui, Ruirong Xu
Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment. Current medicinal chemistry 31 (29) (2024)
Liming Yu, Xuewei Yin, Yuping Si, Yan Wang, Jingyi Wang, Siyuan Cui
Efficacy and safety of selinexor in the treatment of AML: A protocol for systematic review and meta-analysis. Medicine 100 (49) (2022)
Xuewei Yin, Chunyi Lyu, Zonghong Li, Qian Wang, Yi Ding, Yan Wang, Yan Qiu, Siyuan Cui, Dadong Guo, Rui-Rong Xu
High Expression of ACOT2 Predicts Worse Overall Survival and Abnormal Lipid Metabolism: A Potential Target for Acute Myeloid Leukemia. Journal of healthcare engineering 2022 (2022)